Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal

Drug-induced liver injury (DILI) with nintedanib has emerged as an adverse event of special interest in premarketing clinical trials. We characterized DILI with nintedanib in the real world and explored the underlying pharmacological basis. First, we assessed serious hepatic events reported to the F...

Full description

Bibliographic Details
Published in:	Pharmaceuticals
Main Authors:	Emanuel Raschi, Michele Fusaroli, Milo Gatti, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Subjects:	drug-induced liver injury FAERS spontaneous reporting system pharmacovigilance disproportionality pharmacokinetics
Online Access:	https://www.mdpi.com/1424-8247/15/5/645

Similar Items

Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)
by: Dao-chun Xiang, et al.
Published: (2024-09-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database
by: Wen-Long Xie, et al.
Published: (2024-10-01)

Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance
by: Monia Donati, et al.
Published: (2025-04-01)

Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database
by: Ye Hu, et al.
Published: (2025-02-01)

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Pan Ding, et al.
Published: (2025-03-01)

Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Dan Zhao, et al.
Published: (2024-05-01)

Post-marketing safety surveillance of voclosporin: an observational, pharmacovigilance study leveraging faers database study on the safety of voclosporin
by: Zhi Wang, et al.
Published: (2025-05-01)

Risk Factors for Drug-Induced Acute Generalized Exanthematous Pustulosis(AGEP) from 2004 to 2024: A Real-World Study Based on the FAERS
by: Que H, et al.
Published: (2025-10-01)

Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system
by: Fengfen Liu, et al.
Published: (2025-03-01)

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database
by: Fang Wu, et al.
Published: (2025-02-01)

Real world pharmacovigilance assessment of drug related macular degeneration risks
by: Xiaodong Chen, et al.
Published: (2025-01-01)

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
by: Yi Zheng, et al.
Published: (2023-01-01)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
by: Qilin Zhang, et al.
Published: (2023-08-01)

A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
by: Lisha Wu, et al.
Published: (2024-08-01)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024-11-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline
by: Michele Fusaroli, et al.
Published: (2024-11-01)

Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database
by: Lingli Huang, et al.
Published: (2025-09-01)

Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database
by: Dan Xu, et al.
Published: (2024-10-01)

Drug-associated congenital anomalies of the external ear identified in the United States food and drug administration adverse event reporting system database
by: Xinyu Li, et al.
Published: (2024-10-01)

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2024-06-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
by: Heenam Seo, et al.
Published: (2023-01-01)

Adverse events of ursodeoxycholic acid: a real-world pharmacovigilance study using FAERS (2004–2023)
by: Yahui Ni, et al.
Published: (2025-09-01)

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system
by: Yu Zhang, et al.
Published: (2024-12-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database
by: Xiang Li, et al.
Published: (2025-04-01)

Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database
by: Zhiwen Fu, et al.
Published: (2024-06-01)

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database
by: Ya-Jun Zhang, et al.
Published: (2024-12-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021-02-01)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024-02-01)

Sex-specific risk signals and onset patterns of drug-induced peripheral neuralgia: a 20-year pharmacovigilance analysis based on FAERS real-world dat
by: Xianyan Wang, et al.
Published: (2025-08-01)

Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database
by: Mengjiao He, et al.
Published: (2025-02-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)